ReviewBone reports2026
Lipid nanoparticles for nucleic acid delivery to osteoblasts and osteoblast-lineage cells: A systematic review.
Review in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipid nanoparticle (LNP) delivery of nucleic acids is a promising therapeutic platform for addressing bone disorders. A review of LNP formulations that have been studied for nucleic acid delivery to osteoblasts and osteoblast-lineage cells may help guide development of LNPs that are optimized for nucleic acid treatment of bone disorders. Methods: In October 2025, a search of PubMed, Embase, and Web of Science was conducted to systematically review studies on LNPs that have been evaluated for nucleic acid delivery to osteoblasts and osteoblast-lineage cells. Nine studies were included for analysis. Results: In the nine included studies, 11 LNPs were evaluated for nucleic acid delivery to osteoblasts or osteoblast-lineage cells. The LNPs were formulated with various ionizable/cationic lipids, helper lipids, PEGylated lipids, and bone-targeting ligands. They carried mRNA, siRNA, or long non-coding RNA cargos. All LNPs were capable of transfecting target cells with nucleic acids in vitro and/or delivering nucleic acids to bone tissues in rodent models. The delivery efficiency differed between LNPs with different formulations. Cytotoxicity of ionizable LNPs in cell cultures was minimal, and in vivo adverse effects were limited to elevated inflammatory markers for certain LNP formulations. Conclusions: This study catalogs 11 different LNP formulations that are effective for delivery of nucleic acids to bone cells in in vitro and/or in vivo models. Differences in performance and formulation of these LNPs can help inform optimization of LNP formulation for nucleic acid treatment of bone disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.